SLC5A2 and type 2 diabetes mellitus: The CANVAS Program, which consists of the CANVAS study and CANVAS-R, CVOTs assessed the cardiovascular safety and efficacy of the SGLT2 inhibitor canagliflozin in patients with type 2 diabetes and established cardiovascular disease, and also revealed that canagliflozin reduced the risk of a composite outcome of major adverse cardiovascular events in comparison to a matching placebo (9) (Table 1).